Skip to main content
SpringerLink
Log in

A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

The issue of ecstasy-related fatalities has extensively attracted the attention of both the media and the general public, but less so of the scientific literature.

Objectives

The aim of the present review is to focus on the epidemiological, clinical and pharmacological issues related to ecstasy fatalities.

Results

Possibly due to a number of different reasons, the rates of ecstasy-related deaths seem to have peaked in recent years. MDMA metabolism is regulated by the levels of CYP2D6 and COMT (both exhibit some genetic polymorphism), and range of activity of these enzymes may account for some inter-individual differences in terms of toxic responses to the drug. A small increase in MDMA dosage can lead to a significant rise in drug plasma concentration. Due to their tolerance to MDMA psychoactive effects, some individuals may binge with dosages that may be the cause of serious concern. In experienced users, a reverse tolerance phenomenon can also be observed. Together with ecstasy, most of the misusers take a number of different compounds and the possible rationale of this style of consumption is commented upon here. Frequently, the lethal complications observed after acute MDMA administration can be the consequence of the occurrence of a serotonin syndrome and/or of sympathomimetic overstimulation (both conditions are exacerbated by environmentally induced overheating).

Conclusions

A number of methodological problems can contribute to making difficult the interpretation of the role played by ecstasy in so-called ecstasy-related deaths, especially so if accurate information is not available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills. JAMA 284:2190

    CAS  PubMed  Google Scholar 

  • Bal T, Griffin M (2002) Drug Abuse Trends No 18, January—March 2002. Drugs Intelligence Unit, Forensic Science Service, Birmingham

  • Braback L, Humble M (2001) Young woman dies of water intoxication after taking one tablet of ecstasy. Today’s drug panorama calls for increased vigilance in health care. Lakartidningen 98:817–819

    CAS  PubMed  Google Scholar 

  • Budisavljevic MN, Stewart L, Sahn SA, Ploth DW (2003) Hyponatremia associated with 3,4-methylenedioxymethylamphetamine (“ecstasy”) abuse. Am J Med Sci 326:89–93

    Article  PubMed  Google Scholar 

  • Byard RW, Gilbert J, James R, Lokan RJ (1998) Amphetamine derivative fatalities in South Australia: is “ecstasy” the culprit? Am J Forensic Med Pathol 19:261–265

    Article  CAS  PubMed  Google Scholar 

  • Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002a) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531–1536

    Article  PubMed  Google Scholar 

  • Cole JC, Sumnall H, Grob C (2002b) Sorted: ecstasy facts and fiction. Psychologist 15:464–467

    Google Scholar 

  • Cooper AJ, Egleston CV (1997) Accidental ingestion of ecstasy by a toddler: unusual cause for convulsion in a febrile child. J Accid Emerg Med 14:183–184

    CAS  PubMed  Google Scholar 

  • Cottler LB, Womack SB, Compton WM, Ben-Abdallah A (2001) Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol Clin Exp 16:599–606

    Article  CAS  Google Scholar 

  • Curran HV, Travill RA (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): week-end “high” followed by mid-week low. Addiction 92:821–31

    Article  CAS  PubMed  Google Scholar 

  • Dafters RI (1994) Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) in rats. Psychopharmacology 114:505–508

    Google Scholar 

  • Davison D, Parrott AC (1997) Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol Clin Exp 12:91–97

    Article  Google Scholar 

  • de la Torre R, Farre M, Roset PN, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225–237

    PubMed  Google Scholar 

  • Dowling GP, McDonough ET 3rd, Bost R (1987) “Eve” and “ecstasy”. A report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615–1617

    CAS  PubMed  Google Scholar 

  • EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2003) Annual report. The state of the drugs problem in the European Union and Norway. Office for the Official Publications of the European Communities, Luxembourg

  • Ener RA, Meglathery SB, Van Decker WA, Gallagher RM (2003) Serotonin syndrome and other serotonergic disorders. Pain Med 4:63–74

    PubMed  Google Scholar 

  • Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965:399–409

    CAS  PubMed  Google Scholar 

  • Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC (1998) Recent paramethoxyamphetamine deaths. J Anal Toxicol 22:169–172

    CAS  PubMed  Google Scholar 

  • Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135:649–656

    CAS  PubMed  Google Scholar 

  • Fox HC, Parrott AC, Turner JJ (2001) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15:273–281

    CAS  PubMed  Google Scholar 

  • Ghodse AH, Oyefeso A, Webb L, Pollard M, Corkery J (2001) Drug-related deaths as reported by coroners in England and Wales. Annual review 2000 and np-SAD Surveillance Report no. 7. European Centre for Addiction Studies, St George’s Hospital Medical School, London, UK

  • Ghodse AH, Oyefeso A, Webb L, Schifano F, Pollard M, Jambert-Gray R, Corkery J (2002) Drug-related deaths as reported by coroners in England and Wales. Annual review 2001 and np-SAD report no. 9. European Centre for Addiction Studies, St George’s Hospital Medical School, London, UK

  • Ghodse AH, Schifano F, Oyefeso A, Jambert-Gray R, Cobain K, Corkery J (2003) Drug-related deaths as reported by coroners in England and Wales. Annual review 2002 and np-SAD report no. 11. European Centre for Addiction Studies, St George’s Hospital Medical School, London, UK

  • Gilhooly TC, Daly AK (2002) CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 54:69–70

    Article  CAS  PubMed  Google Scholar 

  • Gill JR, Hayes JA, deSouza IS, Marker E, Stajic M (2002) Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci 47:121–126

    PubMed  Google Scholar 

  • Gillmann PK (1999) The serotonin syndrome and its treatment. J Psychopharmacol 13:100–109

    PubMed  Google Scholar 

  • Giroud C, Augsburger M, Sadeghipour F, Varesio E, Veuthey JL, Rivier L (1997) Ecstasy—the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity. Schweiz Rundsch Med Prax 86:510–23

    CAS  PubMed  Google Scholar 

  • Goldberger BA, Gold MS (2002) Ecstasy deaths in the state of Florida. A post-mortem analysis. Biol Psychiatry 192s:57

    Google Scholar 

  • Gore SM (1999) Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet 354:1265–1266

    Article  CAS  PubMed  Google Scholar 

  • Green AR, Grahame-Smith DG (1976) Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature 260:487–491

    CAS  PubMed  Google Scholar 

  • Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”). Psychopharmacology 119:247–260

    CAS  PubMed  Google Scholar 

  • Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55:463–508

    Article  CAS  PubMed  Google Scholar 

  • Harrington RD, Woodward JA, Hooton TM, Horn JR (1999) Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Int Med 159:2221–2224

    Article  CAS  Google Scholar 

  • Hedetoft C, Christensen HR (1999) Amphetamine, ecstasy and cocaine. Clinical aspects of acute poisoning. Ugeskr Laeger 161:6907–6911

    CAS  PubMed  Google Scholar 

  • Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20:432–440

    CAS  PubMed  Google Scholar 

  • Henry JA, Hill IR (1998) Fatal interaction between ritonavir and MDMA. Lancet 352:1751–1752

    Article  CAS  Google Scholar 

  • Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet 340:384–387

    CAS  PubMed  Google Scholar 

  • Heydari A, Rowland Yeo K, Rostami-Hodjegan A, Lennard MS, Tucker GT (2003) Ecstasy (MDMA) is a mechanism-based inhibitor of CYP2D6. J Psychopharmacol 17:A36

    Google Scholar 

  • Hooft PJ, van de Voorde HP (1994) Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing. Int J Legal Med 106:328–329

    CAS  PubMed  Google Scholar 

  • Hoshi R, Rees H, Hoare T, Bond A, Curran HV (2003) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. J Psychopharmacol 17:A33

    Google Scholar 

  • Huether G, Zhou D, Ruther E (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners. J Neural Transm 104:771–794

    CAS  PubMed  Google Scholar 

  • Hunt N (2003) Ecstasy deaths. Did alcohol play a part? BMJ.com; Available from: http://bmj.bmjjournals.com/cgi/eletters/326/7380/80 (accessed on 19.11.2003)

  • King LA (2000) Was it MDMA? Neuropsychobiology 42:45–46

    Google Scholar 

  • Kovar KA (1998) Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Pharmacopsychiatry 31:69–72

    CAS  PubMed  Google Scholar 

  • Landry MJ (2002) MDMA: a review of epidemiological data. J Psychoactive Drugs 34:163–169

    Google Scholar 

  • Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) in healthy volunteers. J Psychopharmacol 14:269–274

    Google Scholar 

  • Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (“ecstasy”). Toxicol Lett 113:133–142

    Article  Google Scholar 

  • McKenna C (2002) Ecstasy is low in league table of major causes of deaths. BMJ 325:296

    Article  Google Scholar 

  • Merrill J (1996) Ecstasy and neurodegeneration. Advice is that “less is more”. BMJ 313:423

    CAS  Google Scholar 

  • Milani R, Turner JJD, Parrott AC, Parmar R (2000) Recreational drug use and psychobiological problems, collaborative UK/Italy study (5): ecstasy (MDMA) polydrug findings. J Psychopharmacol 14:A15

    Google Scholar 

  • National Crime Intelligence Service (2002) Streetwise publication 1994–2002. National Criminal Intelligence Service, London, UK

  • Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965:421–433

    CAS  PubMed  Google Scholar 

  • Parr MJ, Low HM, Botterill P (1997) Hyponatraemia and death after “ecstasy” ingestion. Med J Aust 166:136–137

    CAS  PubMed  Google Scholar 

  • Parrott AC (2001) Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol Clin Exp 16:557–577

    Google Scholar 

  • Parrott AC (2002) Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844

    Google Scholar 

  • Parrott AC (2003) Chronic tolerance to recreational ecstasy or MDMA: a new underlying mechanism. J Psychopharmacol 17:A34

    Google Scholar 

  • Parrott AC, Milani RM, Parmar R, Turner JD (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77–82

    CAS  PubMed  Google Scholar 

  • Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM (2002) Reduced (±)-3,4-methylenedioxymethamphetamine (“ecstasy”) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63:2111–2119

    Article  CAS  PubMed  Google Scholar 

  • Ramsay M, Baker P, Goulden C, Sharp C, Sondhi A (2001) Drug misuse declared in 2000: results from the British Crime Survey. Home Office Research Study 224. Home Office Research Development and Statistics Directorate, London, UK

  • Ramsey JD, Butcher MA, Murphy MF, Lee T, Johnston A, Holt DW (2001) A new method to monitor drugs at dance venues. BMJ 323:603

    CAS  PubMed  Google Scholar 

  • Ricaurte GA, Yuan J, McCann UD (2000) (±)3,4-Methylenedioxymethamphetamine (“ecstasy”)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5–10

    CAS  PubMed  Google Scholar 

  • Schifano F (1995) Dangerous driving and MDMA (“ecstasy”) abuse. J Serotonin Res 1:53–57

    Google Scholar 

  • Schifano F (2000) Potential human neurotoxicity of MDMA (“ecstasy”): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33

    CAS  PubMed  Google Scholar 

  • Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA (“ecstasy”) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 1:85–90

    Article  Google Scholar 

  • Schifano F, Serpelloni G, Gerra G (2000) Effetti da assunzione protratta di ecstasy. In: Serpelloni G, Schifano F (eds) Linee guida per la prevenzione dell’overdose da eroina e degli effetti acuti dell’ecstasy. Regione del Veneto, Verona (I)

  • Schifano F, Leoni M, Martinotti G, Rawaf S, Rovetto F (2003a) Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. Cyberpsychol Behav 6:405–410

    Article  PubMed  Google Scholar 

  • Schifano F, Oyefeso A, Corkery J, Cobain K, Jambert-Gray R, Martinotti G, Ghodse AH (2003b) Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002. Hum Psychopharmacol Clin Exp 18:519–524

    Article  CAS  Google Scholar 

  • Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003c) Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ 326:80–81

    Article  PubMed  Google Scholar 

  • Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de La Torre R (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol l4:1203–1208

    Article  Google Scholar 

  • Soar K, Fox H, Turner JJD, Parrott AC (2003) The relationship between problematic ecstasy use, dosage and the serotonin syndrome. J Psychopharmacol 17:A35

    Google Scholar 

  • Spruit IP (1999) Ecstasy use and policy response in The Netherlands. J Drug Issues 29:653–678

    Google Scholar 

  • Steele TD, McCann UD, Ricaurte GA (1994) 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89:539–551

    CAS  PubMed  Google Scholar 

  • Theune M, Esser W, Druschky KF, Interschick E, Patscheke H (1999) Grand mal seizures after ecstasy abuse. Nervenarzt 70:1094–1097

    Article  CAS  PubMed  Google Scholar 

  • Tossmann P, Boldt S, Tensil MD (2001) The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 7:2–23

    Article  CAS  PubMed  Google Scholar 

  • Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994) The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151–1156

    CAS  PubMed  Google Scholar 

  • Van Heeringen C, Marusic A (2003) Understanding the suicidal brain. Br J Psychiatry 183:282–284

    Article  PubMed  Google Scholar 

  • Vollenweider FX, Benz MA, Hasler F, Ludewig S, Studerus E, Lindner K (2003) Investigation of the role of 5-HT1A receptors in the psychopharmacology of MDMA (ecstasy). J Psychopharmacol 17:A35

    Google Scholar 

  • Vuori E, Henry JA, Ojanpera I, Nieminen R, Savolainen T, Wahlsten P, Jantti M (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98:365–368

    Article  PubMed  Google Scholar 

  • Webb L, Oyefeso A, Schifano F, Cheeta S, Pollard M, Ghodse AH (2003) Causes and manner of death in drug-related fatality: an analysis of drug-related deaths recorded by coroners in England and Wales in 2000. Drug Alcohol Depend 24:67–74

    Article  Google Scholar 

  • Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A (1998) “Saturday night fever”: ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 15:322–326

    CAS  PubMed  Google Scholar 

  • Winstock AR, Wolff K, Ramsey J (2001) Ecstasy pill testing: harm minimization gone too far? Addiction 96:1139–1148

    Article  CAS  PubMed  Google Scholar 

  • Winstock AR, Wolff K, Ramsey J (2002) 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend 67:111–115

    Article  CAS  PubMed  Google Scholar 

  • Zhu BT (2002) Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 3:321–349

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Mental Health-Addictive Behaviour, St George’s Hospital Medical School, University of London, Cranmer Terrace, London, SW17 ORE, UK

    Fabrizio Schifano

Authors
  1. Fabrizio Schifano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabrizio Schifano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schifano, F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 173, 242–248 (2004). https://doi.org/10.1007/s00213-003-1730-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-003-1730-5

Keywords

Search

Navigation